{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:22:55Z","timestamp":1778667775370,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.annder.2012.03.012","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T09:48:47Z","timestamp":1334656127000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Indications et modalit\u00e9s d\u2019utilisation des antagonistes de l\u2019interleukine (IL)-1\u00a0dans les dermatoses inflammatoires"],"prefix":"10.1016","volume":"139","author":[{"given":"D.","family":"Lipsker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lenormand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2012.03.012_bib0005","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1\u00a0in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.annder.2012.03.012_bib0010","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/eji.201141550","article-title":"A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation","volume":"41","author":"Dinarello","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annder.2012.03.012_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2133.1987.tb05836.x","article-title":"Is the pathogenesis of Sweet's syndrome mediated by interleukin-1?","volume":"116","author":"Going","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1046\/j.1365-2133.1996.81843.x","article-title":"An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1\u00a0in 12\u00a0cases of Sweet's syndrome","volume":"134","author":"Bourke","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0025","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0190-9622(98)70266-X","article-title":"Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1\u00a0cytokines?","volume":"39","author":"Giasuddin","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease","volume":"27","author":"Masters","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.annder.2012.03.012_bib0040","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0045","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1\u00a0Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2012.03.012_bib0050","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1\u00a0receptor antagonist in the Muckle-Wells syndrome","volume":"348","author":"Hawkins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0055","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammaytory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0060","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the ILR1N locus","volume":"360","author":"Reddy","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0065","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0070","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5\u00a0are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.annder.2012.03.012_bib0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MD.0b013e3181943f5e","article-title":"Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9\u00a0new cases and review of the literature","volume":"88","author":"Kieffer","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.annder.2012.03.012_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200101000-00004","article-title":"The Schnitzler syndrome. Four new cases and review of the literature","volume":"80","author":"Lipsker","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.annder.2012.03.012_bib0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","article-title":"Schnitzler syndrome: beyond the case reports: review and follow-up of 94\u00a0patients with an emphasis on prognosis and treatment","volume":"37","author":"de Koning","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.annder.2012.03.012_bib0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-1172-5-38","article-title":"The Schnitzler syndrome","volume":"5","author":"Lipsker","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.annder.2012.03.012_bib0095","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.21101","article-title":"Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al","volume":"52","author":"Martinez-Taboada","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2012.03.012_bib0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2340\/00015555-0404","article-title":"Efficacy of interleukin 1\u00a0receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome","volume":"88","author":"Kluger","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2012.03.012_bib0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-3083.2008.02708.x","article-title":"Schnitzler syndrome: a dramatic improvement with anakinra","volume":"23","author":"Wastiaux","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2012.03.012_bib0110","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaci.2011.10.031","article-title":"Complete remission in 3\u00a0of 3\u00a0anti-IL-6-treated patients with Schnitzler syndrome","volume":"129","author":"Krause","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2012.03.012_bib0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2012.03.012_bib0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1\u00a0receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2012.03.012_bib0125","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.annder.2012.03.012_bib0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1\u00a0receptor antagonist, in refractory Sweet syndrome","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2012.03.012_bib0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1\u00a0receptor antagonist anakinra (Kineret) in a case of refractory Sweet syndrome","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2012.03.012_bib0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000280436","article-title":"Anakinra for difficult-to-treat neutrophilic panniculitis. IL-1\u00a0blocade as a promising treatment option in neutrophil-mediated inflammatory skin disease","volume":"220","author":"Lipsker","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2012.03.012_bib0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0150","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","article-title":"Dysregulation of P2X7\u00a0receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra","volume":"49","author":"Colina","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2012.03.012_bib0155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","article-title":"Resistant Beh\u00e7et disease responsive to anakinra","volume":"149","author":"Botsios","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2012.03.012_bib0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/kel041","article-title":"Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1\u00a0receptor antagonist (anakinra)","volume":"45","author":"Vounotrypidis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2012.03.012_bib0165","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jbspin.2008.02.011","article-title":"Efficacy of anakinra in a patient with refractory relapsing polychondritis","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.annder.2012.03.012_bib0190","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/archdermatol.2011.2473","article-title":"Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra","volume":"148","author":"Lutz","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0175","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1002\/ibd.21684","article-title":"Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1\u00a0gene","volume":"17","author":"Lin","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2012.03.012_bib0180","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2012.03.012_bib0185","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963812001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963812001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:59:12Z","timestamp":1758970752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963812001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":38,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0151963812001299"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2012.03.012","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indications et modalit\u00e9s d\u2019utilisation des antagonistes de l\u2019interleukine (IL)-1\u00a0dans les dermatoses inflammatoires","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2012.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}